NetworkNewsBreaks – Predictive Oncology Inc.’s
Post# of 281
(Total Views: 176)
Posted On: 02/08/2021 3:24:14 PM
NetworkNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics Launches Project Focused on Ovarian Cancer Utilizing Proprietary PeDAL(TM) Platform
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it will start an in-house drug repurposing project, focused on ovarian cancer, using its proprietary AI-driven, patient centric discovery platform – PeDAL(TM). The project will use PeDAL to rapidly and cost-effectively profile panel of existing drugs against hundreds of patient cell lines. “With our Helomics division’s deep experience in clinical profiling of patient tumor drug response, plus our unique PeDAL platform, we have all the components to perform in-house drug repositioning and even full drug discovery. We are very excited to kick-off this first project focused on ovarian cancer,” said Dr. Carl Schwartz, CEO of Predictive Oncology. “Our expectations are that the project will have significant value by generating proof data for our PeDAL approach, which will be useful in our commercial discussions with pharmaceutical companies. In addition, the project will also demonstrate the long-term value of Helomics unique data.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it will start an in-house drug repurposing project, focused on ovarian cancer, using its proprietary AI-driven, patient centric discovery platform – PeDAL(TM). The project will use PeDAL to rapidly and cost-effectively profile panel of existing drugs against hundreds of patient cell lines. “With our Helomics division’s deep experience in clinical profiling of patient tumor drug response, plus our unique PeDAL platform, we have all the components to perform in-house drug repositioning and even full drug discovery. We are very excited to kick-off this first project focused on ovarian cancer,” said Dr. Carl Schwartz, CEO of Predictive Oncology. “Our expectations are that the project will have significant value by generating proof data for our PeDAL approach, which will be useful in our commercial discussions with pharmaceutical companies. In addition, the project will also demonstrate the long-term value of Helomics unique data.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Predictive Oncology Inc. (POAI) Stock Research Links
Scroll down for more posts ▼